Pulling SEC filings + quote and writing the call…
| Fiscal year | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|
| Revenue | $5.13B | $5.41B | $5.97B | $6.32B |
| Revenue growth | — | 5.5% | 10.3% | 6.0% |
| Net income | $189M | $53.9M | $210M | $136M |
| Net margin | 3.7% | 1.0% | 3.5% | 2.1% |
| EPS (diluted) | $1.50 | $0.43 | $1.58 | $0.96 |
| Fiscal year | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|
| Operating cash flow | -$38.4M | $222M | $315M | $471M |
| Dividends paid | $175M | $0.00 | $0.00 | — |
| Fiscal year | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|
| Cash & equivalents | $456M | $438M | $557M | $710M |
| Total assets | — | $4.73B | $4.96B | $5.29B |
| Total liabilities | — | $3.65B | $3.43B | $3.61B |
| Long-term debt | — | $1.17B | $1.09B | $1.08B |
| Shareholders' equity | $1.04B | $671M | $1.13B | $1.29B |
| Retained earnings | — | $155M | $366M | $502M |
| Shares (wtd avg diluted) | 126M | 126M | 133M | 141M |
Every figure is extracted from Ardent Health, Inc.’s annual reports as filed with the SEC (XBRL company facts) — no third-party estimates. Fiscal years are labeled by period end; filers occasionally re-tag concepts, so a sparse cell means the company didn’t report that concept for that year. Free cash flow = operating cash flow − capital expenditures.
Research and education only — not financial advice. TENKis not a registered investment adviser or broker-dealer and gives no personalized advice. Every call is impersonal — identical for all users, generated on a schedule from SEC filings plus a delayed/third-party price feed — may be wrong or out of date, and is not a recommendation to buy or sell any security. The operator and an affiliated trading operation may hold or trade the securities TENK rates; see Disclosures. Past performance does not guarantee future results. Do your own research.